Proteomics International launches predictive test for diabetic kidney disease in Australia on World Kidney Day
Proteomics International Laboratories Ltd (ASX:PIQ) is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. Founded in 2001, the Company specialises in proteomics – the industrial scale study of the structure and function of proteins.
Proteomics International’s mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International is a wholly-owned subsidiary and trading name of Proteomics International Laboratories Ltd (PILL; ASX: PIQ)
Proteomics International’s business model is to bring its pipeline of novel diagnostic tests, exemplified by PromarkerD, PromarkerEndo, PromarkerEso and OxiDx, to major markets across the world, and offset the cash burn from R&D and product development through its analytical services revenue, coupled with the R&D tax incentive rebate. This diversified model enables the group to make optimum use of its resources.
.png "Line 14 (1)")
Proteomics is the large-scale mapping of the structure and function of proteins.
- Unlike our genes, the protein make-up in our bodies differs from cell to cell and changes considerably over time. For example, a cancerous cell will have significantly different proteins to a healthy cell.
- The caterpillar and butterfly have exactly the same genes but differences in their proteins cause dramatic differences during the lifecycle.
.png "Frame (1)")
“We have been working with Proteomics International for last 2-3 years for availing the analytical services of Biosimilars/Biologics Drug Characterisation. Our experience has been excellent. PI has offered us timely support to meet the time-lines by completing the sample analysis with data interpretations within the specified time frames. The data and the analysis reports were shared with Regulatory Agency and got accepted. PI was very prompt in answering the queries raised by the Agency.”